Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Prana Biotechnology Ltd Updates On Clinical Trials


Wednesday, 3 Apr 2013 01:13am EDT 

Prana Biotechnology Ltd announced that on the progress of its lead development asset PBT2 in Phase II trials for Huntington disease and Alzheimer’s disease. Across the two trials approximately 37% have been dosed to 6 months or longer, twice the duration of the previous Phase II Alzheimer’s trial.1,2 PBT2 has been well tolerated and both trials are on schedule with pleasing retention rates and compliance. Each Independent Data Safety Monitoring Board for the two trials met at the end of March and recommended that each trial continue as planned without any protocol changes. In an earlier 12 week trial PBT2 both significantly changed amyloid levels in spinal fluid and improved the cognition of patients with Alzheimer’s disease.1,2 The IMAGINE trial, with 12 months of treatment, aims to establish PBT2 as a safe and effective treatment for Alzheimer’s disease. The randomized, double-blind, placebo controlled trial has enrolled 41 patients with prodromal or mild Alzheimer’s disease in five sites in Melbourne, Australia. Brain Imaging is being used to measure PBT2’s effect on amyloid deposits in the brain (using PiB-PET scanning) and effects on increasing brain activity (FDG PET). Cognition effects are being measured by the Neuropsychological Test Battery (NTB). The Reach2HD trial is a 6 month trial in 109 patients with early to mid-stage Huntington disease. The trial is being conducted across sites in the USA and Australia. 

Company Quote

2.61
0.05 +1.95%
11 Jul 2014